Cephalexin
- Generic Name
- Cephalexin
- Brand Names
- Keflex
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N3O4S
- CAS Number
- 15686-71-2
- Unique Ingredient Identifier
- 5SFF1W6677
- Background
Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis. Cephalexin was approved by the FDA on 4 January 1971.
- Indication
Cephalexin is indicated for the treatment of certain infections caused by susceptible bacteria. These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.
- Associated Conditions
- Bone Infection, Genitourinary tract infection, Otitis Media (OM), Respiratory Tract Infections (RTI), Skin and skin structure infections, Acute Prostatitis
FDA Approves Orlynvah, a New Oral Penem Antibiotic, for Uncomplicated UTIs
• The FDA has approved Orlynvah (sulopenem etzadroxil and probenecid) as the first oral penem antibiotic for uncomplicated urinary tract infections (uUTIs).
• Orlynvah is indicated for adult women with uUTIs caused by specific bacteria, including Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, when other oral options are limited.
• Clinical trials demonstrated Orlynvah's superiority over ciprofloxacin in fluoroquinolone-resistant infections and statistical superiority to Augmentin in Augmentin-susceptible cases.
• Orlynvah offers a new treatment option to combat antimicrobial resistance, particularly in quinolone-resistant organisms and ESBL-producing E. coli, potentially reducing hospitalizations.
Clindamycin and Bacterial Load Reduction Evaluated for Surgical Site Infection Prophylaxis in Skin Cancer Excision
• A randomized, double-blinded, placebo-controlled trial is underway in Tropical North Queensland to assess the efficacy of clindamycin and bacterial load reduction in preventing surgical site infections (SSI).
• The study involves three arms: bacterial load reduction (nasal mupirocin and chlorhexidine wash), oral clindamycin, and a control group receiving placebos, targeting patients undergoing flap or graft procedures for skin cancer below the knee.
• The primary outcome is the incidence of postoperative SSI, with secondary outcomes including adverse reactions, microbiology of infected wounds, antibiotic resistance patterns, and cost-effectiveness.
• The trial aims to reduce patient morbidity, promote antibiotic stewardship, and potentially change clinical practice by determining if either intervention significantly decreases SSI rates in complex skin surgeries.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath